PRECIGEN INC (PGEN)
Health Care · Gene therapy and cell therapy biopharmaceuticals · NASDAQ
Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and viral vector candidates across oncology and infectious disease.
What PRECIGEN INC does
Precigen is a commercial-stage biopharmaceutical company developing precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases using proprietary gene therapy platforms. The company commercialized Papzimeos (zopapogene imadenovec-drba), an FDA-approved adenoviral vector-based immunotherapy for treating adults with recurrent respiratory papillomatosis (RRP), and maintains a clinical pipeline of candidates built on its AdenoVerse immunotherapy and UltraCAR-T therapeutic platforms.
Themes: ["Gene therapy / viral vector delivery","Immunotherapy - cancer and viral disease","CAR-T cell therapy manufacturing","Precision medicine","Synthetic biology platforms","Rare disease treatment"]
Fundamentals
- Price$5.53 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+191.1% as of 2026-07-09 close
- Net margin-647.0% as of 2026-07-10
- Gross margin+80.1% as of 2026-07-10
- ROE-642.5% as of 2026-07-10
- Debt / equity4.62 as of 2026-07-10
- Revenue growth (YoY)+652.1% as of 2026-07-10
- Revenue CAGR (3y)-28.9% SEC XBRL
- Beta1.05 as of 2026-07-10
Key risks (from latest filing)
["Limited commercial revenue - company is newly commercial stage with single approved product (Papzimeos) which must be ramped; high cash burn from R&D operations and negative net margins of -647%","Gene therapy safety and efficacy challenges - reliance on novel adenoviral and CAR-T platforms with manufacturing complexity and regulatory scrutiny inherent to cell/gene therapies","Pipeline risk - portfolio paused or deprioritized (PRGN-3005, PRGN-3007 enrollment halted); clinical development timelines and regulatory approval uncertainties for remaining candidates"]
Competitors & peers
- Juno Therapeutics (JUNO)
- Gilead Sciences (GILD)
- Novartis (NVS)
- Celgene/Bristol Myers Squibb (BMY)
- Sangamo Therapeutics (SGMO)
- REGENXBIO (RGNX)
- Editas Medicine (EDIT)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.